Jacobio Pharma announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora an Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a highly selective small molecule Aurora A inhibitor. At present, there is no commercialized Aurora A inhibitor globally. Jacobio's self-developed JAB-2485 is the third Aurora A inhibitor entered into clinical stage in the United States.

This clinical trial will be completed independently by the clinical team of Jacobio, marking the further improvement of Jacobio's global R&D capability. JAB-2485 has good anti-tumor activity. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels.

The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B and has potential to benefit patients with small cell lung cancer and triple-negative breast cancer. Relevant studies have shown that Aurora A and SHP2 inhibitors may be one of the therapies to solve the drug resistance of KRAS G12C inhibitors and is also expected to enhance the anti-tumor effect in combination with BET inhibitors. Jacobio has these three self-developed drugs in clinical stage, including SHP2 inhibitors (JAB-3312, JAB-3068), Aurora A inhibitor (JAB-2485), KRAS G12C inhibitors (JAB-21822), and BET inhibitors (JAB-8263), which has potential to provide more combination therapies to patients.

About clinical study of JAB-2485 The clinical study of JAB-2485 (NCT05490472) is an open, phase I/IIa international multicenter study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JAB-2485 in the treatment of advanced solid tumors. This global multicenter study will enroll 102 patients and is expected to be completed in August 2026.